Acute myeloid leukemia (AML) is a rare subtype of acute leukemia in the pediatric and
adolescent population but causes disproportionate morbidity and mortality in this age group …

Immunotherapy has made significant advancements in cancer treatments, improving
patients' survival rates and quality of life. Several challenges still need to be addressed …

Acute myeloid leukemia (AML) is a blood cancer caused by the abnormal proliferation and
differentiation of hematopoietic stem cells in the bone marrow. The actual genetic markers …

Introduction Chronic graft-versus-host disease (cGVHD) is a debilitating side effect of
allogeneic hematopoietic cell transplantation (HCT), affecting the quality of life of patients …

Abstract Myc target 1 (MYCT1), located at 6q25. 2, is a crucial player in cancer development.
While widely distributed in cells, its subcellular localization varies across different cancer …

Simple Summary Survival rates for children with acute myeloid leukemia have significantly
improved in recent decades. Still, 20–30% will succumb to therapy-related toxicity and …

Background Relapse in pediatric acute myeloid leukemia (pedAML) patients is known to be
associated with residual leukemic stem cells (LSC). We have previously shown that …

Background Cholangiocarcinoma (CCA) is a fatal cancer of the bile duct with a poor
prognosis owing to limited therapeutic options. The incidence of intrahepatic CCA (iCCA) is …

Acute myeloid leukemia is the most common acute leukemia in adults, with accumulation of
abundant blasts and impairment of hematogenic function. Despite great advances in …

Accumulating studies have indicated that N6-methyladenosine (m 6 A) plays an important
role in acute myeloid leukaemia (AML). However, little is known about the m 6 A methylome …